Akums Drugs & Pharmaceuticals Ltd
Fundamental Score
Akums Drugs & Pharmaceuticals Ltd Share Price Live NSE/BSE
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of AKUMS across key market metrics for learning purposes.
Positive Indicators
8 factors identified
Strong Return on Equity (17.19%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (16.20%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance. This indicates quality business fundamentals.
Attractive Valuation (P/E: 21.76 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity if fundamentals support the business case.
Strong Profit Growth Track Record (48.93% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model and effective operational leverage over time.
Conservative Debt Levels (D/E: 0.03)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns and flexibility for growth investments.
Strong Interest Coverage (6.61x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk and strong debt servicing capability.
Strong Cash Generation (₹132.48 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral, reducing forced-selling risk.
Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.
Risk Factors
3 factors identified
Profit Decline Concern (-34.83%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes. Monitor for recovery signs and management guidance.
Weak Earnings Growth (-42.93% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation. Consider growth catalysts and competitive positioning.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints. Assess capital allocation strategy.
Financial Statements
Comprehensive financial data for Akums Drugs & Pharmaceuticals Ltd
About AKUMS
Business Overview
Akums Drugs and Pharmaceuticals Limited manufactures and sells pharmaceutical products and active pharmaceutical ingredients India and internationally. The company provides drugs, ayurvedic, herbals, toiletries, nutraceuticals, food and dietary supplements, derma and cosmetics, healthcare and hospital products, over-the-counter (OTC) products, active pharmaceutical ingredients, excipients, and compounds. It also offers branded formulations on various dosage forms, including tablets, capsules, injectables, opthalmics, and soft gelatin capsules for therapeutic areas, such as gynaecology, cardiology, orthopaedics, pediatrics, and dermatology, as well as anti-infectives, pain management and gastroenterology. In addition, the company operates as pharmaceutical contract development and manufacturing company. The company was incorporated in 2004 and is based in Delhi, India.
Company Details
Key Leadership
Latest News
AKUMS Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of Akums Drugs & Pharmaceuticals Ltd (AKUMS)?
As of 30 Jan 2026, 01:38 pm IST, Akums Drugs & Pharmaceuticals Ltd (AKUMS) is currently trading at ₹439.55. The stock has a market capitalization of ₹6.70K (Cr).
Is AKUMS share price Overvalued or Undervalued?
AKUMS is currently trading at a P/E ratio of 21.76x, compared to the industry average of 31.77x. Based on this relative valuation, the stock appears to be Undervalued against its sector peers.
What factors affect the Akums Drugs & Pharmaceuticals Ltd share price?
Key factors influencing AKUMS's price include its quarterly earnings growth (Sales Growth: -1.51%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Akums Drugs & Pharmaceuticals Ltd a good stock for long-term investment?
Akums Drugs & Pharmaceuticals Ltd shows a 5-year Profit Growth of 48.93% and an ROE of 17.19%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.03 before investing.
How does Akums Drugs & Pharmaceuticals Ltd compare with its industry peers?
Akums Drugs & Pharmaceuticals Ltd competes with major peers in the Pharmaceuticals. Investors should compare AKUMS's P/E of 21.76x and ROE of 17.19% against the industry averages to determine its competitive standing.
What is the P/E ratio of AKUMS and what does it mean?
AKUMS has a P/E ratio of 21.76x compared to the industry average of 31.77x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹22 for every ₹1 of annual earnings.
How is AKUMS performing according to Bull Run's analysis?
AKUMS has a Bull Run fundamental score of 46.1/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.
What sector and industry does AKUMS belong to?
AKUMS operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Akums Drugs & Pharmaceuticals Ltd.
What is Return on Equity (ROE) and why is it important for AKUMS?
AKUMS has an ROE of 17.19%, which indicates excellent management efficiency and profitable operations. Return on Equity measures how efficiently Akums Drugs & Pharmaceuticals Ltd generates profits from shareholders' equity.
How is AKUMS's debt-to-equity ratio and what does it indicate?
AKUMS has a debt-to-equity ratio of 0.03, which indicates conservative financing with low financial risk. A ratio below 1.0 generally indicates conservative financing.
What is AKUMS's dividend yield and is it a good dividend stock?
AKUMS offers a dividend yield of 0.00%, which means you receive ₹0.00 annual dividend for every ₹100 invested.
How has AKUMS grown over the past 5 years?
AKUMS has achieved 5-year growth rates of: Sales Growth 11.27%, Profit Growth 48.93%, and EPS Growth -42.93%.
What is the promoter holding in AKUMS and why does it matter?
Promoters hold 75.26% of AKUMS shares, with 0.00% of promoter shares pledged. High promoter holding often indicates strong management confidence.
What is AKUMS's market capitalization category?
AKUMS has a market capitalization of ₹6697 crores, placing it in the Mid-cap category.
How volatile is AKUMS stock?
AKUMS has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is the 52-week high and low for AKUMS?
AKUMS has a 52-week high of ₹N/A and low of ₹N/A.
What is AKUMS's operating profit margin trend?
AKUMS has a 5-year average Operating Profit Margin (OPM) of 5.62%, indicating the company's operational efficiency.
How is AKUMS's quarterly performance?
Recent quarterly performance shows YoY Sales Growth of -1.51% and YoY Profit Growth of -34.83%.
What is the institutional holding pattern in AKUMS?
AKUMS has FII holding of 2.27% and DII holding of 9.28%. Significant institutional holding often suggests professional confidence in the stock.